Alx Oncology Holdings (ALXO) EBIT Margin (2019 - 2020)
Alx Oncology Holdings recorded quarterly EBIT Margin of 2046.87% in Q2 2020, down 155.76% quarter-over-quarter from 800.31% in Q1 2020, and down 172339.0% year-over-year from N/an in Q3 2019.
Alx Oncology Holdings' EBIT Margin history runs 2 years deep, the most recent figure standing at 2046.87% for Q2 2020.
- In Q2 2020, EBIT Margin fell 172339.0% year-over-year to 2046.87%; the TTM figure through Mar 2021 stood at 3514.42% (down 305735.0% YoY), while the FY2020 annual figure was 808.38%, down 40840.0% from the prior year.
- EBIT Margin came in at 2046.87% for Q2 2020 at Alx Oncology Holdings, down from 800.31% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 241.56% in Q3 2019 to a low of 2046.87% in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -2,046.87% |
| Mar 31, 2020 | -800.31% |
| Dec 31, 2019 | -637.51% |
| Sep 30, 2019 | -241.56% |
| Jun 30, 2019 | -323.47% |